Macular oedema (retinal vein occlusion) - dexamethasone: review decision - January 2015 information
History
A list of downloadable documents created during development.
Background information
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: appendix A
-
Macular oedema (retinal vein occlusion) - dexamethasone: appendix A (PDF 77 KB)
-
Macular oedema (retinal vein occlusion) - dexamethasone: review proposal November 2014 information
-
Macular oedema (retinal vein occlusion) - dexamethasone: Appendix B - proposal paper presented to the Institutes Guidance Executive
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: Appendix A - provisional matrix of stakeholders
-
Macular oedema (retinal vein occlusion) - dexamethasone: equality impact assessment
-
Macular oedema (retinal vein occlusion) - dexamethasone: equality impact assessment
-
Macular oedema (retinal vein occlusion) - dexamethasone: equality impact assessment (PDF 69 KB)
Macular oedema (retinal vein occlusion) - dexamethasone: final appraisal determination
-
Macular oedema (retinal vein occlusion) - dexamethasone: final appraisal determination information
-
Macular oedema (retinal vein occlusion) - dexamethasone: final appraisal determination document
-
-
Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
-
-
Consultee and commentator comments on the ACD
-
Allergan cover letter
-
-
Allergen response to ACD
-
-
Allergan additional analysis
-
-
Appendices to the additional analysis
-
-
RNIB ACD comments
-
-
RCO ACD comments
-
-
RCN ACD comments
-
-
NHS Waltham Forest ACD comments
-
-
Comments on the ACD received from the public through the NICE website
-
NHS Wirrall
-
-
NHS Bradford and Airedale
-
-
Additional ERG critique post ACD by Aberdeen HTA Group
-
Additional ERG critique post ACD by Aberdeen HTA Group (PDF 1.04 MB)
Macular oedema (retinal vein occlusion) - dexamethasone: appraisal consultation
-
Macular oedema (retinal vein occlusion) - dexamethasone: appraisal consultation
-
Macular oedema (retinal vein occlusion) - dexamethasone: appraisal consultation document information
-
Macular oedema (retinal vein occlusion) - dexamethasone: evaluation report
-
Macular oedema (retinal vein occlusion) - dexamethasone: pre-meeting briefing
-
Macular oedema (retinal vein occlusion) - dexamethasone: pre-meeting briefing (PDF 290 KB)
-
Macular oedema (retinal vein occlusion) - dexamethasone: final scope
-
Macular oedema (retinal vein occlusion) - dexamethasone: final scope (PDF 61 KB)
-
Macular oedema (retinal vein occlusion) - dexamethasone: final matrix
-
Macular oedema (retinal vein occlusion) - dexamethasone: final matrix (PDF 49 KB)
-
Macular oedema (retinal vein occlusion) - dexamethasone: manufacturer submissions
-
Macular oedema (retinal vein occlusion) - dexamethasone: submission from Allergan Pharmaceuticals
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: submission from Allergan Pharmaceuticals - additional analyses
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: clarification letters
-
Macular oedema (retinal vein occlusion) - dexamethasone: NICE request to the manufacturer for clarification on their submission
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: Manufacturer's response to NICE's request for clarification
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: non-manufacturer submissions
-
Macular oedema (retinal vein occlusion) - dexamethasone: submission from Macular Disease Society and Royal National Institute of Blind People (RNIB) (joint submission)
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: submission from Macular Disease Society and Royal National Institute of Blind People (RNIB) (joint submission) - case study A
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: submission from Macular Disease Society and Royal National Institute of Blind People (RNIB) (joint submission) - case study B
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: submission from Macular Disease Society and Royal National Institute of Blind People (RNIB) (joint submission) - case study C
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: submission from Macular Disease Society and Royal National Institute of Blind People (RNIB) (joint submission) - case study D
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: submission from Royal College of Nursing
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: submission from Royal College of Ophthalmologists
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: submission from Royal College of Ophthalmologists - Interim Guidelines for Management of Retinal Vein Occlusion
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: expert personal statements
-
Macular oedema (retinal vein occlusion) - dexamethasone: expert personal statement - McLaughlan
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: expert personal statement - Pearce
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: expert personal statement - Read
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: expert personal statement - Taylor
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: evidence review group report
-
Macular oedema (retinal vein occlusion) - dexamethasone: Evidence Review Group report
-
Macular oedema (retinal vein occlusion) - dexamethasone: Evidence Review Group report (PDF 1.47 MB)
-
Macular oedema (retinal vein occlusion) - dexamethasone: Evidence Review Group report - additional analyses
-
-
Macular oedema (retinal vein occlusion) - dexamethasone: Evidence Review Group report - factual accuracy check
-
Macular oedema (retinal vein occlusion) - dexamethasone: final scope
-
Macular oedema (retinal vein occlusion) - dexamethasone: final scope
-
Macular oedema (retinal vein occlusion) - dexamethasone: final scope (PDF 61 KB)
Macular oedema (retinal vein occlusion) - dexamethasone: final matrix
-
Macular oedema (retinal vein occlusion) - dexamethasone: final matrix
-
Macular oedema (retinal vein occlusion) - dexamethasone: final matrix (PDF 48 KB)
Macular oedema (retinal vein occlusion) - dexamethasone: Institute's response to consultee and commentator comments on the draft scope
-
Macular oedema (retinal vein occlusion) - dexamethasone: Institute's response to consultee and commentator comments on the draft scope
-
Macular oedema (retinal vein occlusion) - dexamethasone: Institute's response to consultee and commentator comments on the draft scope
-
Macular oedema (retinal vein occlusion) - dexamethasone: Institute's response to consultee and commentator comments on the draft scope
-
Appendix B: draft scope for consultation (pre-referral)
-
Appendix B: draft scope for consultation (pre-referral)
-
Appendix B: draft scope for consultation (pre-referral) (PDF 34 KB)
Appendix C: provisional matrix (pre-referral)
-
Appendix C: provisional matrix (pre-referral)
-